Long-term outcomes after switching from baricitinib 4 mg to upadacitinib 30 mg in atopic dermatitis: A 144-week retrospective study - 01/06/26
Doi : 10.1016/j.jaad.2026.05.013
Teppei Hagino, MD, PhD a, ⁎ 
, Hidehisa Saeki, MD, PhD b, Eita Fujimoto, MD, PhD c, Naoko Kanda, MD, PhD a
, Hidehisa Saeki, MD, PhD b, Eita Fujimoto, MD, PhD c, Naoko Kanda, MD, PhD a a Department of Dermatology, Nippon Medical School Chiba Hokusoh Hospital, Inzai, Japan
b Department of Dermatology, Nippon Medical School, Tokyo, Japan
c Department of Dermatology, Fujimoto Dermatology Clinic, Funabashi, Japan
∗ Correspondence to: Teppei Hagino, MD, PhD, Department of Dermatology, Nippon Medical School Chiba Hokusoh Hospital, Kamagari 1715, Inzai, Chiba 270-1694, Japan Department of Dermatology Nippon Medical School Chiba Hokusoh Hospital Kamagari 1715, Inzai Chiba 270-1694 Japan
Sous presse. Épreuves corrigées par l'auteur.
Disponible en ligne depuis le Monday 01 June 2026
Key words : atopic dermatitis, baricitinib, Janus kinase, switch, upadacitinib
| Funding sources: This work is partly supported by 2025 scholarship grant from Maruho Takagi Dermatology Foundation . |
|
| Patient consent: Informed consent was obtained from all subjects involved in the study. |
|
| IRB approval status: This study was conducted in accordance with the Declaration of Helsinki, and approved by the Ethics Committee of Nippon Medical School Chiba Hokusoh Hospital, and Nippon Medical school. |
© 2026
Publié par Elsevier Masson SAS.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?